The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses

References

• Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103–124.
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Chronic spontaneous urticaria: pathogenesis and treatment considerations. Allergy Asthma Immunol Res. 2017;9(6):477–482.
   PubMed Web of Science ®Google Scholar
• Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(4):441–446.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Watanabe Y, Tashiro Y, et al. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome. J Dermatol Sci. 2017;88(3):320–329.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Alhilali K, Alzahrani A, et al. Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy. 2019. DOI:https://doi.org/10.1111/all.13769
   Google Scholar
• Chen WT, Wang CW, Lu CW, et al. The function of HLA-B*13:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions. J Invest Dermatol. 2018;138(7):1546–1554.
   PubMed Web of Science ®Google Scholar
• Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol. 2012;92(2):194–199.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019;155(6):666-672.
   PubMed Web of Science ®Google Scholar
• Cai F, Lucas M, Yun J. Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01. Intern Med J. 2018;48(3):363–364.
   PubMed Web of Science ®Google Scholar
• Oh HL, Kang DY, Kang HR, et al. Severe cutaneous adverse reactions in korean pediatric patients: a study from the korea SCAR registry. Allergy Asthma Immunol Res. 2019;11(2):241–253.
   PubMed Web of Science ®Google Scholar
• Richardus JH, Smith TC. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr Rev. 1989;60(4):267–273.
   PubMed Web of Science ®Google Scholar
• Kang MG, Sohn KH, Kang DY, et al. Analysis of individual case safety reports of severe cutaneous adverse reactions in Korea. Yonsei Med J. 2019;60(2):208–215.
   PubMed Web of Science ®Google Scholar
• Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303–307.
   PubMed Web of Science ®Google Scholar
• Lee KW, Oh DH, Lee C, et al. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens. 2005;65(5):437–447.
   PubMedGoogle Scholar
• Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160.
   PubMed Web of Science ®Google Scholar
• Wang H, Yan L, Zhang G, et al. Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. J Invest Dermatol. 2013;133(11):2642–2644.
   PubMed Web of Science ®Google Scholar
• Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620–1628.
   PubMed Web of Science ®Google Scholar
• Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics. 2017;27(12):429–437.
   PubMed Web of Science ®Google Scholar
• Chen CB, Abe R, Pan RY, et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res. 2018;2018:6431694.
   PubMed Web of Science ®Google Scholar
• Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015–1018.
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
   PubMed Web of Science ®Google Scholar
• Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–2091.
   PubMed Web of Science ®Google Scholar
• Genin E, Chen DP, Hung SI, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 2014;14(3):281–288.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee KW, Song WJ, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011;97(1–2):190–197.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010;51(2):297–300.
   PubMed Web of Science ®Google Scholar
• Ramirez E, Bellon T, Tong HY, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017;115:168–178.
   PubMed Web of Science ®Google Scholar
• Nguyen DV, Vida C, Chu HC, et al. Validation of a rapid, robust, inexpensive screening method for detecting the HLA-B*58:01 allele in the prevention of allopurinol-induced severe cutaneous adverse reactions. Allergy Asthma Immunol Res. 2017;9(1):79–84.
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim YJ, Kim DH, et al. HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS/TEN according to culprit drugs. Yonsei Med J. 2016;57(1):118–126.
   PubMed Web of Science ®Google Scholar
• Rao PN, Lakshmi TS. Increase in the incidence of dapsone hypersensitivity syndrome--an appraisal. Lepr Rev. 2001;72(1):57–62.
   PubMed Web of Science ®Google Scholar
• Wang N, Parimi L, Liu H, et al. A review on dapsone hypersensitivity syndrome among chinese patients with an emphasis on preventing adverse drug reactions with genetic testing. Am J Trop Med Hyg. 2017;96(5):1014–1018.
   PubMed Web of Science ®Google Scholar